About
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of...
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.
- 22Feb21News ReleaseImmunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
- 18Feb21
- 1Feb21
- 22Jan21News ReleaseReport from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021
- 21Jan21
- 5Oct20
- 30Sep20News ReleaseImmunicum AB Announces Update on Corporate and Clinical Development Strategy
- 21Sep20
- 18Sep20
- 17Sep20News ReleaseImmunicum AB (publ) Presents Preclinical Data on Ilixadencel in Combination with Cancer Therapies and Immunotherapies at the 2020 Virtual ESMO Congress
- 14Sep20News ReleaseImmunicum AB (publ) Announces Publication of Abstract for the ESMO Virtual Congress 2020
- 28Aug20News ReleaseImmunicum AB (publ) Announces the Appointment of Sven Rohmann as Chief Executive Officer
- 27Aug20
- 18Aug20
- 18Aug20News ReleaseImmunicum AB (publ) Announces Update on Survival Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer
- 24Jun20Company PresentationEstablishing a unique immuno-oncology approach by developing allogeneic, off-the-shelf, cell-based therapies
- 16Jun20News ReleaseImmunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Gastrointestinal Stromal Tumors (GIST) in Cancer Immunology, Immunotherapy
- 15Jun20News ReleaseImmunicum AB (publ) Announces Advancement to a Non-Staggered Inclusion Phase in the Phase Ib/II ILIAD Combination Trial
- 2Jun20
- 13May20News ReleaseImmunicum AB (publ) Announces Appointment of Peter Hein as Interim Chief Financial Officer
- 6May20News ReleaseImmunicum AB (publ) Receives Regenerative Medicine Advanced Therapy Designation from FDA for Ilixadencel in Kidney Cancer
- 28Apr20
- 28Apr20
- 15Apr20Company PresentationEstablishing a unique immuno-oncology approach by developing allogeneic, off-the-shelf, cell-based therapies. April 2020
- 3Apr20
- 30Mar20News ReleaseImmunicum AB (publ) Announces Peter Suenaert to Resume Role as Chief Medical Officer
- 27Mar20
- 12Mar20Corporate UpdateASCO Post Article / Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer
- 2Mar20News ReleaseImmunicum AB (publ) Announces that its CFO, Michaela Gertz, Will Leave the Company this Summer
- 26Feb20
- 18Feb20
- 12Feb20
- 6Feb20
- 6Feb20News ReleaseImmunicum AB Presents Updated Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer at ASCO-SITC Clinical Immuno-Oncology Symposium
- 5Feb20
- 3Feb20News ReleaseImmunicum AB (publ) Announces Publication of Abstracts for the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
- 6Jan20
- 13Dec19
- 2Dec19
- 6Nov19
- 6Nov19
- 6Nov19
- 31Oct19
- 24Oct19
- 21Oct19News ReleaseImmunicum AB (publ) Announces Positive Preclinical Data on Ilixadencel in Combination with CTLA-4 Immune Checkpoint Inhibitor
- 14Oct19
- 9Oct19
- 1Oct19News ReleaseImmunicum AB (publ) Announces Advancement to Next Dosage Group Level in Phase Ib/II ILIAD Combination Trial
- 25Sep19
- 25Sep19News ReleaseImmunicum AB (publ) Announces Complete Topline Data Analysis from Phase II MERECA Trial
- 4Sep19
- 30Aug19
- 29Aug19
- 29Aug19News ReleaseImmunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma Patients
- 20Aug19
- 20Aug19
- 11Jul19
- 28Jun19News ReleaseImmunicum AB (publ) Announces New Issuance Date for Interim Report April – June 2019 and Corporate Update Event
- 12Jun19News ReleaseImmunicum AB (publ) Announces Positive Topline Results from the Phase I/II Clinical Trial in GIST
- 29May19
- 28May19News ReleaseImmunicum AB (publ) Announces Outcome of Subscription in Employee Incentive Program 2019/2022
- 22May19
- 7May19
- 29Apr19
- 25Apr19News ReleaseReport from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019
- 25Apr19
- 25Apr19
- 25Apr19
- 4Apr19
- 3Apr19
- 26Mar19
- 21Feb19
- 15Feb19
- 15Feb19
- 11Feb19News ReleaseImmunicum AB (publ) Announces First Patient Treated in Phase Ib/II ILIAD Combination Trial
- 31Jan19News ReleaseChange in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue
- 30Jan19
- 21Jan19News ReleaseImmunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology
- 28Dec18News ReleaseChange in Number of Shares and Votes in Immunicum AB (publ) After Completed Directed Issue
- 13Dec18News ReleaseImmunicum AB (publ) Publishes the Outcome in the Share Issues and Raises SEK 351M
- 8Nov18News ReleaseReport from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018
- 7Nov18
- 7Nov18
- 7Nov18
- 22Oct18News ReleaseImmunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018
- 19Oct18
- 1Oct18News ReleaseImmunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration
- 17Sep18News ReleaseImmunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board
- 17Aug18
- 17Aug18
- 13Aug18News ReleaseImmunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress
- 23Jul18News ReleaseImmunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial
- 18Jun18News ReleaseImmunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research
- 21May18News ReleaseImmunicum AB (publ) Announces End of Enrollment in Phase I/II GIST Clinical Trial
- 4May18
- 4May18
- 3Apr18News ReleaseImmunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program
- 20Mar18News ReleaseImmunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data
- 14Mar18News ReleaseThe Nomination Committee of Immunicum AB (publ) proposes Michael Oredsson as new Chairman of the Board